Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
Status:
Not yet recruiting
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of durvalumab in combination with lenvatinib
in participants with advanced and recurrent endometrial carcinoma.The primary hypothesis of
this study are that patients with advanced and recurrent endometrial carcinoma could benefit
from durvalumab plus lenvatinib with respect to: 1)Progression Free Survival (PFS) ; 2)
Objective Response Rate (ORR); and Overall survival (OS). The investigators design a clinical
study to explore whether the combination above as a treatment in patients with advanced and
recurrent endometrial carcinoma could prolong PFS and to analyze potential immune biomarker
of therapeutic response.